NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...

Two of the simplest ways to measure the success of companies that develop and commercialize drugs is to count their approvals ...

Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the ...

Among the first presentations at the European Society for Medical Oncology (ESMO) meeting that kicked off today, were results ...

Today’s positive decision follows the manufacturer, Daiichi Sankyo, offering a fair price for the treatment that the National Institute for Health and Care Excellence (NICE) determined to be ...

Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.

GlobalData forecasts predict Enhertu will retain its dominant market position in the ADC treatment landscape. The most common ...

As a result, commercial teams are evolving as valuable partners to HCPs. From educating key experts before launch and ...

An investigational once-weekly insulin was noninferior to a daily option for patients with type 2 diabetes, but proved risky ...

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.